Biofrontera AG buy stratec
Summary
This prediction ended on 01.05.19 with a price of €6.99. The prediction had a final performance of 21.35%. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Biofrontera AG | - | - | - | - |
| iShares Core DAX® | -1.226% | 2.804% | 14.933% | 16.561% |
| iShares Nasdaq 100 | -1.845% | 2.732% | 26.075% | 54.743% |
| iShares Nikkei 225® | -1.132% | -2.218% | 5.361% | 4.560% |
| iShares S&P 500 | -0.980% | 1.883% | 22.727% | 45.760% |
Comments by stratec for this prediction
In the thread Biofrontera AG diskutieren
stratec stimmt der Buy-Einschätzung der institutionellen Analysten zu
Biofrontera is seeking to become a leader in the treatment of sun-induced skin cancers using photodynamic therapy, proceeds from their IPO will aid in their growth aspirations, the recent IND filing for basal cell carcinoma adds another expansion opportunity and recent approval in Europe should also boost revenues going forward.
Opinion: With several growth drivers including a possible advantage over competition (Sun Pharmaceuticals' Levulan) in efficacy and reimbursement (daylight PDT approval allowing Ameluz to be eligible for reimbursement in the self-applied topical market), this is definitely a story on which to do further due diligence. Including the basal cell carcinoma market the peak sales potential for Ameluz reaches over $700 million, when combined with the likelihood of taking away market share from Levulan and accelerating sales (aided by receipt of product specific J-code) this looks like a very interesting long-term Buy.